Ultragenyx Pharmaceutical (RARE) Total Liabilities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Total Liabilities data on file, last reported at $1.5 billion in Q1 2026.

• Quarterly Total Liabilities rose 31.39% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 31.39% YoY) and the FY2025 annual result came in at $1.6 billion, up 29.33% from the prior year.
• Total Liabilities fell to $1.5 billion in Q1 2026 per RARE's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $1.6 billion in Q4 2025 and bottomed at $587.6 million in Q1 2022.
• The 5-year median for Total Liabilities is $1.2 billion (2023), against an average of $1.2 billion.
• The widest annual swing landed in 2022, when Total Liabilities soared 108.6%; it then decreased 3.21% in 2025.
• Tracing RARE's Total Liabilities over 5 years: stood at $1.2 billion in 2022, then grew by 1.9% to $1.2 billion in 2023, then gained by 2.09% to $1.2 billion in 2024, then climbed by 29.33% to $1.6 billion in 2025, then retreated by 4.98% to $1.5 billion in 2026.
• Per Business Quant, the three latest RARE Total Liabilities figures stand at $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.2 billion (Q3 2025).

Peer Comparison